

Form for disclosing material information

Date	29 March 2021
Name of the Listed Company	Gulf Pharmaceutical Industries Julphar
The Material Information	The company entered into a contract manufacturing agreement with G42 Medications Trading LLC for the production of COVID-19 vaccines from Sinopharm and is expected to start commercial production in April 2021.
The financial period in which the financial impact will appear	2021 onwards

The Name of the Authorized Signatory	Jurgen Wolfgang Lauterbach
Designation	CFO & Chief Strategy Officer
Signature and Date	29 March 2021 
Company's Seal	